TRASTUZUMAB IN HER2 POSITIVE EARLY BREAST CANCER: A RETROSPECTIVE AUDIT IN A REGIONAL CANCER CENTER

被引：0
|
作者：
Heng, Sharon [1 ]
Pokharel, Khageshwor [1 ]
Gilbar, Peter [1 ]
Tannock, Margot [1 ]
机构：
[1] Toowoomba Base Hosp, Dept Med Oncol, Toowoomba, Qld, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
321
引用
收藏
页码：153 / 153
页数：1
相关论文
共 50 条
  • [41] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [42] ADJUVANT TC (DOCETAXEL/CYCLOPHOSPHAMIDE)-HER (TRASTUZUMAB) (TC-HER) IN HER2 POSITIVE BREAST CANCER
    Hara, F.
    Kiyoto, S.
    Takahashi, M.
    Takabatake, D.
    Takashima, S.
    Aogi, K.
    Ohsumi, S.
    BREAST, 2013, 22 : S87 - S87
  • [43] Optimal duration of trastuzumab for early HER2-positive breast cancer
    Specht, Jennifer M.
    Davidson, Nancy E.
    LANCET, 2017, 389 (10075): : 1167 - 1168
  • [44] IMMUNOTHERAPY FOR HER2 POSITIVE BREAST CANCER
    Vaidya, T. R.
    Ait-Oudhia, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S20 - S20
  • [45] Her2 positive breast cancer: practices
    Campone, Mario
    Berton-Rigaud, Dominique
    Bourbouloux, Emmanuelle
    Sophie, Sadot
    Zanetti, Alain
    Frenel, Jean-Sebastien
    BULLETIN DU CANCER, 2011, 98 (02) : 154 - 163
  • [46] Alternative targeted therapy for early Her2 positive breast cancer
    Harvey, Sandra L.
    Khasraw, Mustafa
    GLAND SURGERY, 2013, 2 (01) : 42 - 45
  • [47] Delayed breast cancer surgery in HER2 positive breast cancer
    Hur, Ho
    Le, Amy
    Chang, Helena R.
    CANCER RESEARCH, 2020, 80 (04)
  • [48] SAFETY AND TOLERABILITY OF SUBCUTANEOUS TRASTUZUMAB AS A TREATMENT IN PATIENTS WITH EARLY HER 2 POSITIVE BREAST CANCER : EXPERIENCE OF A CANCER CENTER IN PERU
    Otoya, Iris
    Valdivieso, Natalia
    Morante, Zaida
    Castaneda, Carlos
    Neciosup, Silvia
    Calderon, Monica
    Gomez, Henry
    CANCER RESEARCH, 2024, 84 (09)
  • [49] HER2 POSITIVE EARLY BREAST CANCERS: WHAT PROPORTION ARE RECEIVING ADJUVANT TRASTUZUMAB THERAPY? A MULTICENTRE AUDIT
    Marla, S.
    Cardale, J.
    Dodwell, D. J.
    Skene, A. I.
    Gojis, O.
    Abram, P.
    Palmieri, C.
    Cleator, S. J.
    Bowman, A.
    Doughty, J. C.
    EJC SUPPLEMENTS, 2010, 8 (06): : 14 - 15
  • [50] RETROSPECTIVE ANALYSIS OF CARDIAC MEDICATIONS IN THE PREVENTION OF CARDIOTOXICITY IN TRASTUZUMAB-TREATED HER2 POSITIVE BREAST CANCER PATIENTS
    Moey, Melissa
    Liles, Darla K.
    Carabello, Blase
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 694 - 694
12345